Adhera Therapeutics, Inc. - FORM 8-K - EX-23.1 - CONSENT OF WOLF & COMPANY, P.C. - November 5, 2010

Attached files

file filename
EX-4.1 - FORM OF SUBSCRIPTION INVESTMENT UNIT - Adhera Therapeutics, Inc.dex41.htm
EX-4.2 - FORM OF WARRANT - Adhera Therapeutics, Inc.dex42.htm
EX-10.1 - AMENDMENT TO THE SECURITIES PURCHASE AGREEMENTS - Adhera Therapeutics, Inc.dex101.htm
EX-10.2 - SECURITIES PURCHASE AGREEMENT - Adhera Therapeutics, Inc.dex102.htm
EX-99.1 - PRESS RELEASE - Adhera Therapeutics, Inc.dex991.htm
8-K - CURRENT REPORT ON FORM 8-K - Adhera Therapeutics, Inc.d8k.htm

 

Exhibit 23.1

CONSENT OF INDEPENDENT AUDITOR

We consent to the incorporation by reference into the Prospectus Supplement dated November 5, 2010 to the Registration Statement (No. 333-168447) on Form S-3/A of Marina Biotech, Inc. of our report dated April 12, 2010, with respect to the financial statements of Cequent Pharmaceuticals, Inc. for the years ended December 31, 2009 and 2008 and for the period from November 10, 2003 (inception) to December 31, 2009.

We also consent to the reference to our firm under the caption “Experts” in such Prospectus Supplement.

 

/s/ Wolf & Company, P.C.
Wolf & Company, P.C.
Boston, Massachusetts
November 3, 2010

Adhera Therapeutics, Inc. Reports